I know that this sub is not the biggest fan of medtech/healthcare instruments, especially if the stock has been crashing for months/year straight. But I still did want to share Cochlear because it is a strong business - that has traded for many years as a top med compounder trading close to 50x earnings, but that has severely and unusually missed financial guidance and harshly punished.
Cochlear ltd. provides lifelong implantable hearing solutions, with a 60% market share but still a big TAM, securing room to grow and a wide moat through surgical lock-in and high-margin recurring services. Although the last report in April showed profit decline and emerging market pricing shifts, the structural moat should remain intact. Cochlear’s moat is anchored by extreme switching costs. Once a device is surgically implanted, the recipient is physically locked into the ecosystem for life. This creates a highly predictable "razor-and-blade" revenue model, where the high-margin services segment, accounting for 26% of sales, provides recurring income through mandatory processor upgrades. Even with HY26’s operational headwinds and contracting delays, the installed base remains captive. This structural advantage ensures that short-term rollout fluctuations do not lead to customer loss, as switching to a competitor would require invasive and risky secondary surgery.
Finally, they have over 2k patents in the complex field, and continuously spend massively in R&D.
The last earnings debacle: The April 2026 guidance downgrade, which cut profit from A$435–460m to A$290–330m just eight weeks after the HY26 result, was the largest guidance miss in the company's listed history and by a wide margin. Cochlear implant demand, especially in developed markets, has proven more cyclical and macro-sensitive than previously assumed. This challenges the market's long-held view of Cochlear as a structural, volume-driven growth story largely insulated from economic cycles. The specific headwinds cited were hospital capacity constraints, reduced referral activity from the hearing aid channel, deteriorating US consumer sentiment causing surgery deferrals, Middle East order cancellations and receivables provisions, lower gross margins and restructuring costs.
Valuation:
I do think they are cheap, but again - and as often - it kind of depends on your approach: do you need short/mid-term evidence before buying, or are you ok to buy low and just ride it wild for years? At 19× trailing PE and 12× EV/EBITDA, the stock is priced at a level not seen in over a decade, well below the long-run average. The structural demand picture — fewer than 5% of eligible patients have a cochlear implant globally, and a growing body of evidence links cochlear implants to reduced dementia risk — has not changed.
If earnings normalise to A$450m+ over 2–3 years (the original FY26 expectation before the macro shock), and the market re-rates to even a discounted 28–32× (still well below historical norms), fair value is around A$200-230. If the damage is permanent and earnings stay near A$310m at a lower structural multiple of 20×, the stock would be roughly fairly valued. However, the market gives Cochlear a PEG of 15 - which means the market does not believe AT.ALL. in earnings recovery anytime soon.
Full disclosure: I tend to be the latter (need evidence for recovery) and will not open a position just yet. But I am tempted and will keep looking into it. I have another medtech darling that is Zeiss Meditec and that shows many similarities. But Zeiss Meditec's decline has been much longer - and competition much stronger. So if i want to be honest, it'd make more sense to bet into Cochlear than Zeiss.